There is provided a method for controlling a flow of sperms in a uterine tube of a female patient. The method comprises electrically stimulating a uterine tube wall portion by controlling an implanted stimulation device from at least one of an external control unit and an internal control unit, wherein the electrically stimulating causes contraction of the uterine tube wall portion along a length of the portion to restrict the flow of sperms in the uterine tube.

A skin treatment device using both a radiofrequency and medication and including tightening members, includes a skin expansion module configured to stretch a region of the skin into which first needles are inserted to be tightened, the skin expansion module including a guide body protruding outward from a lower end of a handpiece main body and a pair of tightening members hinge-coupled to hinge shafts provided on a left side and a right side of the guide body to be rotatable, wherein lower ends of the pair of tightening members are spread outward while pressurizing the skin in contact with the skin when the handpiece main body is moved downward.

A method for treating a male impotent patient, the method comprising the steps of cutting the skin of the patient, inserting a dissecting tool and dissecting an area of at least one portion of a tissue wall of a penile portion, and placing a medical device. The medical device comprises a constriction device configured to gently constrict the penile portion to restrict the blood flow leaving the penis, and a stimulation device configured to stimulate the penile portion constricted by the constriction device to at least further restrict the blood flow leaving the penis to achieve erection.

The presently disclosed subject matter is directed to a method of treating cancer, such as (but not limited to) metastatic bladder and breast cancer. The disclosed method comprises using two treatment modalities to synergistically treat primary and secondary tumor cells in a subject. The first element of the method comprises administering a therapeutically effective amount of a plasmonics-active metal nanoparticle to a subject comprising a primary cancer and a distant metastatic site, wherein the nanoparticle concentrates at the primary cancer. The method further comprises exposing the subject to photon radiation at the site of the primary cancer. The second element of the disclosed method comprises administering a therapeutically effective amount of an immune checkpoint modulator to the subject. The synergistic combination provides a rapid, safe, and effective treatment of local and distant lesions, better than each modality alone.

An assembly for delivering tumor-treating fields to a body of a patient can include an electrode subassembly and one or more replaceable adhesive subassemblies. Each adhesive subassembly can have a support layer having a first side and a second side. The support layer can define at least one opening. Each electrode of the electrode subassembly can be received within a respective opening of the at least one opening. A first adhesive can be disposed on the first side of the support layer and can couple the support layer to an inner side of a covering layer of the electrode subassembly at an attachment surface of the covering layer. A biocompatible conductive adhesive can be disposed on the second side of the support layer.

A low-frequency treatment device and a treatment system with enhanced user convenience. An acquisition unit acquires an atmospheric pressure of a position where the low-frequency treatment device is located (step S102), a determination unit determines whether the atmospheric pressure is less than a threshold (step S104), and a treatment portion increases an intensity of low frequency treatment if the atmospheric pressure is less than the threshold (step S108).

An unattended approach can increase the reproducibility and safety of the treatment as the chance of over/under treating of a certain area is significantly decreased. On the other hand, unattended treatment of uneven or rugged areas can be challenging in terms of maintaining proper distance or contact with the treated tissue, mostly on areas which tend to differ from patient to patient (e.g. facial area). Delivering energy via a system of active elements embedded in a flexible pad adhesively attached to the skin offers a possible solution. The unattended approach may include delivering of multiple energies to enhance a visual appearance.

A resonant radio frequency diathermy heat applicator, including a flexible pad, an inductive coil with moderate defined resistance, fixed tuning capacitors, connecting cable and shielding that is broadly tuned to the signal source in a manner that eliminates the requirement for variable tuning elements.

A treatment device for providing a magnetic treatment and a radiofrequency treatment to a body area of a patient. The device includes an energy storage device for storing electric energy, a magnetic field generating device, and a switching device to discharge the electrical energy from the energy storage device to the magnetic field generating device, such that a time-varying magnetic field is generated and provides muscle contraction to a muscle in the body area of the patient. The time-varying magnetic field may have a magnetic field density in a range of 0.1 Tesla to 7 Tesla and a repetition rate in a range of 0.1 Hz to 700 Hz. The device may also include a radiofrequency electrode to generate radiofrequency waves to heat a tissue in the body of the patient. A body of the radiofrequency electrode may include a plurality of openings in a range of 5 to 1000 openings.

Noninvasive neuromodulation combines transcutaneous electrical modulation with heat and/or focused ultrasonic energy. A noninvasive neuromodulation device includes a first bipole electrode pair aligned along a first axis and a second bipole electrode pair aligned along a second axis, the first axis and the second axis defining a plane. A focused ultrasound (FUS) transducer can direct a focused ultrasound beam along a third axis that intersects the plane. A controller is electrically coupled to the first and second bipole electrode pairs and to the focused ultrasound transducer. The controller is configured to apply electrical energy having a frequency of between about 1 Hz to about 100 MHz to the first and second bipole electrode pairs, and to cause the FUS transducer to emit a focused ultrasound beam having a frequency of between about 20 kHz to about 10 MHz.